Comparative Pharmacology
Head-to-head clinical analysis: GANCICLOVIR versus INCIVEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANCICLOVIR versus INCIVEK.
GANCICLOVIR vs INCIVEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
None Documented
None Documented
Clinical Note
moderateGanciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateValganciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Valganciclovir."
Clinical Note
moderateGanciclovir + Mycophenolic acid
"The serum concentration of Mycophenolic acid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateValganciclovir + Mycophenolic acid
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for CrCl <70 mL/min
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Category D/X
Category C
Antiviral
Antiviral
"The serum concentration of Mycophenolic acid can be increased when it is combined with Valganciclovir."